RE: Invest for medium/long term1 Mar 2021 16:18
although MGC isn't in the same markets as KNB or CBX, the only comparison you can make is on contracts. KNB announced a reseller deal last week with no actual numbers attached to the deal in terms of revenue or minimum orders etc, CBX doesn't have a product to sell till the Autumn so no revenue forecasts there.
MGC minimum 40,000 units of ArtemiC order per quarter with Swiss Pharma, with up front 10,000 units order to set the ball rolling, that's smashed the 5,000 units the company said they needed to sell every month to become cashflow positive.
Anyone who has done they're homework can see that MGC is going to be the clear winner out of all these 3.